LMNX - DiaSorin agreed to to acquire Luminex for $1.8B

DiaSorin (DSRLF) agreed to buy Luminex (LMNX) for $1.8B, or $37/share, in an all-cash transaction.The deal represents a 23% premium to holders of Luminex based on the closing price on Feb. 24, the day before reports of a potential deal surfaced. The acquisition represents a 12% premium to Luminex's Friday closing price.The acquisition of the Covid-19 test kit maker is expected to close within Q3 and is subject to Luminex holder approval as well as antitrust and CFIUS regulatory requirements, according to a statement. The purchase is expected to be immediately accretive to DiaSorin's earnings per share post closing.Morgan Stanley acted as lead financial advisor to DiaSorin and Cravath Swaine & Moore LLP and Pedersoli Studio Legale acted as legal advisors. Perella Weinberg acted as financial advisor to Luminex and DLA Piper acted as legal advisor.DiaSorin will hold a conference call on Monday at 8am EST to discuss the acquisition.Bloomberg reported on

For further details see:

DiaSorin agreed to to acquire Luminex for $1.8B